Omeros Corporation Reports Fourth Quarter and Year-End 2015 Financial Results

Go back to Omeros Corporation Reports Fourth Quarter and Year-End 2015 Financial Results

Maxim Positive on Omeros' (OMER) Omidria, OMS721; Reaffirms at 'Buy'

March 8, 2016 12:21 PM EST

Maxim reaffirms Omeros (Nasdaq: OMER) at 'Buy' following Q4 results and initiation of its Phase 3 OMS721 program for the treatment of atypical hemolytic uremic syndrome... More

Omeros (OMER) Tops Q4 Loss Per Share of 52c

March 7, 2016 5:26 PM EST

Omeros (NASDAQ: OMER) reported Q4 EPS of ($0.52), may not compare to analyst estimate of ($0.55). Revenue for the quarter came in at $6.66 million versus the consensus estimate of $5.35 million.

For earnings history and earnings-related data on Omeros (OMER) click here.

... More